557 related articles for article (PubMed ID: 18328989)
1. Fibrodysplasia ossificans progressiva.
Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989
[TBL] [Abstract][Full Text] [Related]
2. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.
Pignolo RJ; Shore EM; Kaplan FS
Pediatr Endocrinol Rev; 2013 Jun; 10 Suppl 2(0 2):437-48. PubMed ID: 23858627
[TBL] [Abstract][Full Text] [Related]
3. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
[TBL] [Abstract][Full Text] [Related]
4. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
Pignolo RJ; Shore EM; Kaplan FS
Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
[TBL] [Abstract][Full Text] [Related]
5. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
6. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K
Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433
[TBL] [Abstract][Full Text] [Related]
7. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
8. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
10. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
[TBL] [Abstract][Full Text] [Related]
11. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].
Katagiri T
Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931
[TBL] [Abstract][Full Text] [Related]
12. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
[TBL] [Abstract][Full Text] [Related]
13. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
[TBL] [Abstract][Full Text] [Related]
14. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
15. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
Shore EM; Kaplan FS
Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
[TBL] [Abstract][Full Text] [Related]
16. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
[TBL] [Abstract][Full Text] [Related]
17. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
18. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
19. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
[TBL] [Abstract][Full Text] [Related]
20. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
